Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake

Cardiovascular Research

Volumn 84, Issue 2, 2009, Pages 309-316

  Lopez Vilchez, Irene ^a   Diaz Ricart, Maribel ^a   White, James G ^b   Escolar, Gines ^a   Galan, Ana M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Platelet activation; Procoagulant effect; Serotonin; Thrombogenicity; Tissue factor

Indexed keywords

CITALOPRAM; DALTEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROCOAGULANT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; THROMBOPLASTIN;

ARTICLE; CARDIOVASCULAR RISK; ELECTRON MICROSCOPY; FLOW CYTOMETRY; HUMAN; PRIORITY JOURNAL; PSEUDOPODIUM; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOGENESIS;

ANTICOAGULANTS; BIOLOGICAL TRANSPORT; BLOOD COAGULATION; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; CITALOPRAM; FLOW CYTOMETRY; HIRUDINS; HUMANS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PSEUDOPODIA; RECOMBINANT PROTEINS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; THROMBIN; THROMBOPLASTIN; TIME FACTORS;

EID: 71549134912     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp205     Document Type: Article

References (45)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250.
2. Giesen PA, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JTet al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999;96:2311-2315.
3. Nemerson Y. Tissue factor-then and now. Thromb Haemost 1995;74: 180-184.
4. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E et al. Intra-vascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003;17:476-478.
5. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-2683.
6. Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP et al. Induction of microparticle and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004;103:4545-4553.
7. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating soluble, thrombogenic protein. Nature 2003;9:458-462.
8. Balasubramanian V, Vele O, Nemerson Y. Local shear conditions and platelet aggregates regulate the incorporation and activity of circulating tissue factor in ex-vivo thrombi. Thromb Haemost 2002;88:822-826.
9. Lopez-Vilchez I, Escolar G, Diaz-Ricart M, Fuste B, Galan AM, White JG. Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thromb Haemost 2007;97:202-211.
10. Vanags DM, Rodgers SE, Duncan EM, Lloyd JV, Bochner F. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline. Br J Pharmacol 1992;106:917-923.
11. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71: 533-554.
12. White JG. Platelet secretory granules and associated proteins. Lab Invest 1993;68:497-498.
13. Shimizu M, Kanazawa K, Matsuda Y, Takai E, Iwai C, Miyamoto Y et al. Serotonin-2A receptor gene polymorphisms are associated with serotonin-induced platelet aggregation. Thromb Res 2003;112:137-142.
14. Nakatani D, Sato H, Sakata Y, Shiotani I, Kinjo K, Mizuno H et al. Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am Heart J 2005; 150:652-658.
15. Fumeron F, Betoulle D, Nicaud V, Evans A, Kee F, Ruidavets JB et al. Serotonin transporter gene polymorphism and myocardial infarction-Etude Cas-te'moins de' l'Infarctus du Myocarde (ECTIM). Circulation 2002; 105:2943-2945.
16. Nishihira K, Yamashita A, Tanaka N, Kawamoto R, Imamura T, Yamamoto R et al. Inhibition of 5-hydroxytryptamine(2A) receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost 2006;4:247-255.
17. Lechin F, van der DB, Orozco B, Jahn E, Rodriguez S, Baez S. Neurophar-macological treatment of refractory idiopathic thrombocytopenic purpura: roles of circulating catecholamines and serotonin. Thromb Haemost 2004;91:1254-1256.
18. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192-2217.
19. Carney RM, Freedland KE, Jaffe AS, Frasure-Smith N, Lesperance F, Sheps DS et al. Depression as a risk factor for post-MI mortality. J Am Coll Cardiol 2004;44:472-474.
20. Carney RM, Freedland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry 2003;54:241-247.
21. Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008;118:1768-1775
22. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Car-diovasc Res 1997;35:2-3.
23. Diaz-Ricart M, Estebanell E, Cases A, Lopez-Pedret J, Castillo R, Ordinas A et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 1999;82:1312-1317.
24. Holmsen H. Significance of testing platelet functions in vitro. Eur J Clin Invest 1994;24(Suppl. 1):3-8.
25. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006;296:397-402.
26. Varadi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004; 10(Suppl. 2):17-21.
27. White JG. The morphology of platelet function. Methods Hematol 1983; 4:1-25.
28. Lozano M, Estebanell E, Cid J, Diaz-Ricart M, Mazzara R, Ordinas A et al. Platelet concentrates prepared and stored under currently optimal conditions: minor impact on platelet adhesive and cohesive functions after storage. Transfusion 1999;39:951-959.
29. Mandal SK, Pendurthi UR, Rao LV. Tissue factor trafficking in fibroblasts: involvement of protease-activated receptor-mediated cell signaling. Blood 2007;110:161-170.
30. Baumgartner HR, Born GV. Effects of 5-hydroxytryptamine on platelet aggregation. Nature 1968;218:137-141.
31. Gomez-Gil E, Gasto C, Diaz-Ricart M, Carretero M, Salamero M, Catalan R et al. Platelet 5-HT2A-receptor-mediated induction of aggregation is not altered in major depression. Hum Psychopharmacol 2002;17:419-424.
32. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Sci 2003;28:307-317.
33. Jin JG, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998;95:8070-8074.
34. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000;95:1694-1702.
35. Szasz R, Dale GL. Thrombospondin and fibrinogen bind serotonin- derivatized proteins on COAT-platelets. Blood 2002;100:2827-2831.
36. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002;415:175-179.
37. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005;3:2185-2192.
38. Escolar G, Diaz-Ricart M, Gomez-Gil E, Serra M, Gasto C, Bozzo J et al. Serotonergic mechanisms: a potential link between affective disorders and cardiovascular risk. Drugs Today (Barc) 2005;41:721-743.
39. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003;108:32-36.
40. Galan AM, Lopez-Vilchez I, Diaz-Ricart M, Gomez E, Gasto C Escolar G. Serotonergic mechanisms enhance platelet-mediated thrombogenicity: inhibitory effects of a selective serotonin reuptake inhibitor. Thromb Haemost 2009; (accepted for publication).
41. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996;37:12-16.
42. Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, Egberts ACG. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164:2367-2370.
43. de Abajo FJ, Montero D, Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006;98:304-310.
44. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost 2005;3:1590-1596.
45. Perez-Pujol S, Aras O, Lozano M, Cocking-Johnson D, Key NS, White JG et al. Stored platelets contain residual amounts of tissue factor: evidence from studies on platelet concentrates stored for prolonged periods. Transfusion 2005;45:572-579.